Clinical Trial Update: Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder [Phase 1]

View source ↗

Summary

Phase I studies of NFC-1 in adolescents with ADHD have completed, providing pharmacokinetic data and safety/tolerability results from a single-dose open-label P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• NFC-1

Snippet

Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company | Conditions: Attention-deficit Hyperactivity Disorder (ADHD) | Phase 1 | Status: COMPLETED